Skip to main content
Premium Trial:

Request an Annual Quote

Fujirebio, Eisai Partnering on Blood-based Biomarkers for Neurodegenerative Disease

NEW YORK – Diagnostics firm Fujirebio and drugmaker Eisai said Monday that they have entered a memorandum of understanding for research into and use of blood-based biomarkers for neurodegenerative diseases.

Under the non-exclusive agreement, they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217 (p-tau 217), the development of diagnostics employing other blood-based markers, and the development and commercialization of in vitro diagnostics.

The two Tokyo-based companies have been conducting joint research on cerebrospinal fluid biomarkers related to Alzheimer's disease, they noted.

In 2022, Fujirebio received de novo classification from the US Food and Drug Administration for its Lumipulse G β-Amyloid Ratio (1-42/1-40) test, which can be used for detecting the presence of the amyloid brain pathology characteristic of Alzheimer's disease. And this year, the company filed its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic test with FDA for regulatory approval.

Further terms of the collaboration were not disclosed.